Welcome to our Newsroom, your go-to source for the latest updates on Galapagos. Explore press releases, insightful blogs, and access our resource hub, complete with company materials, designed to provide media and journalists with comprehensive information about our company’s innovations and milestones
Galapagos reports full year 2023 results and provides outlook for 2024
Galapagos to present new preliminary translational data and previously disclosed data at the European Society for Blood and Marrow Transplantation (EBMT)-European Hematology Association (EHA) 6th European CAR T-cell meeting taking place from 15–17 February 2024 in Valencia, Spain.
Galapagos announced the successful completion of the transaction to transfer its Jyseleca® (filgotinib) business to Alfasigma S.p.A. As previously announced, the transfer includes the entire Jyseleca® business, including the European and UK Marketing Authorizations, and the commercial, medical affairs and development activities for Jyseleca®.
Follow our journey
Do you want to stay up to date on our journey, as we are pioneering for patients?